Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Injection Drug Users Who Know They Have Hepatitis C Practice "Sero-Sharing"

People who inject drugs who know they are hepatitis C virus (HCV) positive are more likely to share syringes and injection equipment with others who are also infected, and less likely to do so with people who are HCV negative or unknown -- the equivalent of sexual "serosorting," according to a report in the December 15, 2013, Journal of Infectious Diseases.

Published
06 December 2013
From
HIVandhepatitis.com
Sofosbuvir for Hepatitis C: Simpler, Shorter, Safer?

The availability of these agents will provide unprecedented opportunities for off-label use of these therapies in many patients, including those with decompensated cirrhosis or chronic kidney disease, pediatric populations, and those with HIV coinfection. Because many of these populations represent relatively small numbers of patients with HCV, it may be difficult to accumulate the requisite data and possibly cost-prohibitive for manufactur

Published
04 December 2013
From
Medscape (requires registration)
China's Struggle With Hepatitis B Discrimination

Job applicants and students are regularly turned down on the basis of the disease. Now, some are fighting back.

Published
04 December 2013
From
The Atlantic
Hepatitis C virus dried on inanimate surfaces can remain infectious for up to six weeks

Dried spots of blood contaminated with hepatitis C virus (HCV) can remain infectious for up to six weeks at normal room temperatures, research published in the online

Published
03 December 2013
By
Michael Carter
Fair Pricing Coalition Disappointed by the High Price of New Janssen Hepatitis C Drug Olysio (simeprevir)

Janssen has set the wholesale acquisition cost, (WAC) for a single 12-week course of Olysio at $66,360. Though this is in parity with current HCV PIs, the FPC believes that all HCV drugs are priced too high. The WAC price of Olysio represents only part of the cost of an anti-HCV regimen, including at least $18,000 in WAC costs of interferon and ribavirin, plus the additional cost of the NS3 Q80K polymorphism screening test recommended by the FDA for all patients before initiating Olysio therapy.

Published
29 November 2013
From
Fair Pricing Coalition
Entecavir + tenofovir works well for people with hepatitis B who have had prior treatment failure

A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated among people with chronic hepatitis B who

Published
29 November 2013
By
Liz Highleyman
Ukraininan HIV patients’ organisation is first-ever NGO to get PR award

The Ukraininan Community Advisory Board (UCAB) is the first-ever NGO, rather than a commercial organisation, to win an annual award in their country for the most successful PR stunt of the year. During the Action, aimed at shaming the Ukraininan government into providing better access to hepatitis C treatment, a hundred of “condemned” people lined up in front of the Government building with the cotton bags on their heads and ropes tied around their necks.

Published
28 November 2013
From
Ukrainian Community Advosory Board
AASLD 2013: Aspirin and Cenicriviroc May Help Reduce Liver Fibrosis

Hepatitis C patients who took low-dose aspirin after liver transplantation experienced slower fibrosis progression, researchers reported at the AASLD Liver Meeting this month in Washington, DC. Two other studies showed that cenicriviroc -- a drug being developed for HIV treatment that blocks both CCR5 and CCR2 cell surface receptors -- had anti-inflammatory and anti-fibrotic activity in mice and rats.

Published
28 November 2013
From
HIVandhepatitis.com
Gilead responds over India patent pressure on HCV drug

Fresh from picking up a positive opinion in Europe for sofosbuvir, Gilead Sciences is facing a battle to get patent protection in India for its much-touted new hepatitis C drug.

Published
27 November 2013
From
PharmaTimes
Faldaprevir effective across patient sub-groups with several baseline characteristics associated with treatment outcomes

The experimental hepatitis C virus (HCV) protease inhibitor is efficacious across a range of subgroups, according to research presented to the recent Liver Meeting 2013, the 64th annual

Published
27 November 2013
By
Michael Carter

Filter by country